Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL4387591 | 0.95 | CHRM2 (0.68) | CHRM2CHRM3 | |
| SCHEMBL1303942 | 0.93 | CHRM2 (0.73) | CHRM2CHRM3 | |
| SCHEMBL942864 | 0.92 | CHRM2 (0.63) | CHRM2CHRM3 | |
| SCHEMBL942924 | 0.91 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL1302814 | 0.91 | CHRM2 (0.64) | CHRM2CHRM3 | |
| SCHEMBL1304070 | 0.91 | CHRM2 (0.70) | CHRM2CHRM3 | |
| SCHEMBL943030 | 0.91 | CHRM2 (0.68) | CHRM2CHRM3 | |
| SCHEMBL943529 | 0.91 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL942554 | 0.90 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL941879 | 0.90 | CHRM2 (0.61) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179019-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-06-05 | — | — | US | claimed |
| US-11858898-B2 | Crystalline freebase forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-01-02 | — | — | US | claimed |
| US-20230303492-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-28 | — | — | US | claimed |
| US-11691948-B2 | Crystalline freebase forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-04 | — | — | US | claimed |
| US-11649209-B2 | Crystalline freebase forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-16 | — | — | US | claimed |
| US-20220388981-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-12-08 | — | — | US | claimed |
| US-20220306580-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-09-29 | — | — | US | claimed |
| US-11390603-B2 | Crystalline forms of a biphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-07-19 | — | — | US | claimed |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | claimed |
| US-20220009890-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-13 | — | — | US | claimed |
| US-20080095708-A1 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-24 | — | — | US | claimed |
| US-20070298112-A1 | salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid; pulmonary disorders | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-27 | — | — | US | claimed |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-12-20 | — | — | US | claimed |
| EP-1856050-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| US-7288657-B2 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | THERAVANCE, INC. (US) | 2007-10-30 | — | — | US | claimed |
| US-20070112027-A1 | Crystalline forms of a biphenyl compound | THERAVANCE, INC. | 2007-05-17 | — | — | US | claimed |
| EP-1723114-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2006099165-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649209-B2 | Crystalline freebase forms of a biphenyl compound | TBCB, FFAR1, CRYAB | CHRM2 870/4885CHRM3 494/4885 |
| US-20070292357-A1 | Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester | CHRM1, CHRM2, CHRM3 | CHRM2 2/4885CHRM3 3/4885 |
| US-11390603-B2 | Crystalline forms of a biphenyl compound | FFAR1, FFAR4, FFAR3 | CHRM2 1912/4885CHRM3 1386/4885 |
| US-11858898-B2 | Crystalline freebase forms of a biphenyl compound | TBCB, FFAR1, CRYAB | CHRM2 870/4885CHRM3 494/4885 |
| US-20080095708-A1 | Biphenyl-2-ylcarbamic acid or biphenyl-2-yluurea derivatives for treatment of respiratory system disorders; chronic obstructive pulmonary disease, asthma; antihistamines, bronchodilator agents; side effect reduction | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
| US-20070112027-A1 | Crystalline forms of a biphenyl compound | FFAR1, FFAR4, FFAR3 | CHRM2 1912/4885CHRM3 1386/4885 |
| US-20230303492-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | TBCB, FFAR1, CRYAB | CHRM2 870/4885CHRM3 494/4885 |
| US-20220388981-A1 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | FFAR1, FFAR4, FFAR3 | CHRM2 1912/4885CHRM3 1386/4885 |
| US-11691948-B2 | Crystalline freebase forms of a biphenyl compound | TBCB, FFAR1, CRYAB | CHRM2 870/4885CHRM3 494/4885 |
| US-20070298112-A1 | salt of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester and phosphoric acid; pulmonary disorders | PLCB1, SLC20A1, SLC34A1 | CHRM2 2697/4885CHRM3 2945/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM2 1/4885CHRM3 3/4885 |
| US-20220306580-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | TBCB, FFAR1, CRYAB | CHRM2 870/4885CHRM3 494/4885 |
| US-20220009890-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | TBCB, FFAR1, CRYAB | CHRM2 870/4885CHRM3 494/4885 |
| US-20250179019-A1 | CRYSTALLINE FREEBASE FORMS OF A BIPHENYL COMPOUND | TBCB, FFAR1, CRYAB | CHRM2 870/4885CHRM3 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.